Drug Profile
DT 200
Alternative Names: DT-200; G 100192; GLPG-0492; SARMs - Galapagos NVLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator ProSkelia
- Developer Akashi Therapeutics; Galapagos NV
- Class Small molecules
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
- Discontinued Cachexia
Most Recent Events
- 22 Feb 2023 Preclinical development in Duchenne muscular dystrophy is ongoing in USA (PO) (Akashi therapeutics pipeline, February 2023)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (PO)
- 15 Sep 2014 Preclinical trials in Duchenne muscular dystrophy in USA (PO)